BR112022000122A2 - Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos - Google Patents

Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos

Info

Publication number
BR112022000122A2
BR112022000122A2 BR112022000122A BR112022000122A BR112022000122A2 BR 112022000122 A2 BR112022000122 A2 BR 112022000122A2 BR 112022000122 A BR112022000122 A BR 112022000122A BR 112022000122 A BR112022000122 A BR 112022000122A BR 112022000122 A2 BR112022000122 A2 BR 112022000122A2
Authority
BR
Brazil
Prior art keywords
compounds
protein ligand
activation protein
fibroblast activation
fibroblast
Prior art date
Application number
BR112022000122A
Other languages
English (en)
Inventor
Aileen Höhne
Anne Bredenbeck
Christian Haase
Christiane Smerling
Dirk Zboralski
Eberhard Schneider
Frank Osterkamp
Jan Ungewiss
Matthias Paschke
Ulrich Reineke
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of BR112022000122A2 publication Critical patent/BR112022000122A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

compostos que compreendem umligante de proteína de ativação de fibroblasto e uso dos mesmos. a presente invenção refere-se a um composto que compreende um peptídeo cíclico e um quelante, e seu uso.
BR112022000122A 2019-07-08 2020-07-08 Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos BR112022000122A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19198813 2019-09-20
PCT/EP2020/069298 WO2021005125A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
BR112022000122A2 true BR112022000122A2 (pt) 2022-04-26

Family

ID=71409439

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000122A BR112022000122A2 (pt) 2019-07-08 2020-07-08 Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos

Country Status (12)

Country Link
US (1) US20220273831A1 (pt)
EP (1) EP3997103A1 (pt)
JP (1) JP2022541753A (pt)
KR (1) KR20220032079A (pt)
CN (3) CN114341159B (pt)
AU (1) AU2020310538A1 (pt)
BR (1) BR112022000122A2 (pt)
CA (1) CA3145340A1 (pt)
CL (1) CL2021003580A1 (pt)
IL (1) IL289675A (pt)
MX (1) MX2022000252A (pt)
WO (1) WO2021005125A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4147053A1 (en) 2020-05-07 2023-03-15 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
US20240139350A1 (en) * 2021-02-01 2024-05-02 Five Eleven Pharma, Inc Radioactively labeled ligand for fibroblast activation protein-alpha imaging agent and preparation method therefor
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
WO2022170732A1 (zh) 2021-02-10 2022-08-18 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
CN118647415A (zh) 2022-02-09 2024-09-13 诺华股份有限公司 包含225锕标记的络合物和铋多价螯合剂的药物组合物
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
CN115304582B (zh) * 2022-07-20 2023-05-12 北京法伯新天医药科技有限公司 FAP-α特异性肿瘤诊断显像剂
EP4311557A1 (en) * 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Fap-targeted antibody-drug conjugates
WO2024052431A1 (en) * 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof
EP4342890A1 (en) 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9813233A (pt) 1997-09-29 2000-08-22 Point Therapeutics Inc Estimulação de células hematopoéticas in vitro
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US7399869B2 (en) 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
JP2010523477A (ja) 2007-03-20 2010-07-15 トラスティーズ オブ タフツ カレッジ 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
CN102203061A (zh) 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
US8999342B2 (en) 2009-10-02 2015-04-07 Ludwig Institute For Cancer Research, Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
EP2804859B1 (en) 2012-01-17 2019-06-12 Universiteit Antwerpen Novel fap inhibitors
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
EP3154638A1 (en) * 2014-06-10 2017-04-19 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CA3026900A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
BR112020008011A2 (pt) 2017-10-23 2020-10-27 The Johns Hopkins University agentes de formação de imagem e radioterapêuticos direcionados à proteína-alfa de ativação de fibroblasto (fap-alfa)

Also Published As

Publication number Publication date
IL289675A (en) 2022-03-01
AU2020310538A1 (en) 2022-01-27
CA3145340A1 (en) 2021-01-14
EP3997103A1 (en) 2022-05-18
WO2021005125A1 (en) 2021-01-14
CL2021003580A1 (es) 2022-08-05
CN118388588A (zh) 2024-07-26
CN118406106A (zh) 2024-07-30
JP2022541753A (ja) 2022-09-27
US20220273831A1 (en) 2022-09-01
KR20220032079A (ko) 2022-03-15
CN114341159A (zh) 2022-04-12
MX2022000252A (es) 2022-02-21
CN114341159B (zh) 2024-04-26

Similar Documents

Publication Publication Date Title
BR112022000122A2 (pt) Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos
CO2019009680A2 (es) Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112016027722A8 (pt) compostos contendo grupo autoimulativo e seu uso
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112021020023A2 (pt) Ligantes de conjugação melhorados
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
BR112017002594A2 (pt) compostos inibidores de cinase de ligação de tank
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CL2019000694A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal.
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
MY200925A (en) Peptide Amide Compound and Preparation Method and Medical use Thereof
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
CO2020003977A2 (es) Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico
BR112023022875A2 (pt) Uso farmacêutico de composto peptídico cíclico
BR112022017192A2 (pt) Variantes de transglutaminase
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
CR20170040A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CL2022001545A1 (es) Composiciones y métodos para tratar y prevenir la influenza